Provided by Tiger Trade Technology Pte. Ltd.

Royalty Pharma plc

45.72
+0.53001.17%
Volume:717.00K
Turnover:32.80M
Market Cap:26.66B
PE:25.67
High:46.10
Open:45.34
Low:45.19
Close:45.19
52wk High:46.10
52wk Low:29.66
Shares:583.17M
Float Shares:379.85M
Volume Ratio:0.62
T/O Rate:0.19%
Dividend:0.88
Dividend Rate:1.92%
EPS(TTM):1.78
EPS(LYR):1.78
ROE:13.20%
ROA:5.15%
PB:4.12
PE(LYR):25.67

Loading ...

Royalty Pharma plc Publishes Q4 2025 Financial Results Call Transcript

Reuters
·
Yesterday

Royalty Pharma (RPRX) Valuation Check After Strong Portfolio Growth And 2026 Guidance Update

Simply Wall St.
·
Feb 14

Royalty Pharma (RPRX) Margin Reset To 32.6% Tests Bullish Profitability Narratives

Simply Wall St.
·
Feb 13

Royalty Pharma price target raised to $51 from $45 at Goldman Sachs

TIPRANKS
·
Feb 12

Bank of America Securities Keeps Their Buy Rating on Royalty Pharma (RPRX)

TIPRANKS
·
Feb 12

Stock Track | Royalty Pharma Plunges 6.31% in Pre-Market After Q4 Sales Miss Estimates

Stock Track
·
Feb 11

Royalty Pharma Q4 adjusted EBITDA beats analyst expectations

Reuters
·
Feb 11

Earnings Flash (RPRX) Royalty Pharma Posts Q4 Revenue $622M

MT Newswires Live
·
Feb 11

Royalty Pharma Q4 net income attributable to shareholders USD 214 million

Reuters
·
Feb 11

Royalty Pharma Reports Q4 and Full Year 2025 Results

THOMSON REUTERS
·
Feb 11

Royalty Pharma: Full Year 2026 Guidance: Portfolio Receipts Expected to Be $3,275 Million to $3,425 Million

THOMSON REUTERS
·
Feb 11

Royalty Pharma Q4 Adjusted Ebitda USD 816 Million VS. Ibes Estimate USD 723.3 Million

THOMSON REUTERS
·
Feb 11

Royalty Pharma CFO Terrance P. Coyne Reports Disposal of Common Shares

Reuters
·
Feb 05

Royalty Pharma EVP Marshall Urist Reports Sale of Common Shares

Reuters
·
Feb 03

Royalty Pharma Shares Rise After UBS Upgrade

MT Newswires Live
·
Jan 31

UBS Upgrades Royalty Pharma to Buy From Neutral, Adjusts Price Target to $49 From $38

MT Newswires Live
·
Jan 31

Assessing Royalty Pharma (RPRX) Valuation After Teva Autoimmune Funding Partnership Attracts Fresh Attention

Simply Wall St.
·
Jan 29

Royalty Pharma Is Maintained at Buy by Citigroup

Dow Jones
·
Jan 27

Royalty Pharma EVP Marshall Urist Reports Disposal of Common Shares

Reuters
·
Jan 27

EVP Marshall Urist Reports Disposal of Royalty Pharma plc Common Shares

Reuters
·
Jan 21